Ratings by Citi (David Lebowitz)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/18/2025 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 7/17/2025 | Schrodinger | SDGR | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2025 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2025 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 6/30/2025 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 6/26/2025 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 6/4/2025 | Blueprint Medicines | BPMC | Upgrade | Neutral (N/A) |
127.79 (129.46) |
1.31% | Details | |
| 6/3/2025 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Blueprint Medicines | BPMC | Maintain | Sell (N/A) |
|
Details | ||
| 5/13/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 5/13/2025 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/7/2025 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2025 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2025 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2025 | Cytokinetics | CYTK | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2025 | Pliant Therapeutics | PLRX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2025 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2025 | Pliant Therapeutics | PLRX | Downgrade | Neutral (Buy) |
11.95 (1.43) |
-88.03% | Details | |
| 2/7/2025 | Viking Therapeutic | VKTX | New Coverage | Neutral (N/A) |
31.46 (32.01) |
1.75% | Details | |
| 2/7/2025 | Cytokinetics | CYTK | New Coverage | Buy (N/A) |
46.17 (37.23) |
-19.36% | Details | |
| 1/8/2025 | Celldex Therapeutics | CLDX | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2024 | PTC Therapeutics | PTCT | Maintain | Sell (N/A) |
|
Details | ||
| 11/27/2024 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/18/2024 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 11/15/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2024 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2024 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2024 | Incyte | INCY | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2024 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2024 | PTC Therapeutics | PTCT | Maintain | Sell (N/A) |
|
Details | ||
| 10/14/2024 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 10/10/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2024 | Celldex Therapeutics | CLDX | New Coverage | Buy (N/A) |
30.84 (22.41) |
-27.33% | Details | |
| 9/24/2024 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/16/2024 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2024 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2024 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 9/3/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2024 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 6/20/2024 | PTC Therapeutics | PTCT | Maintain | Sell (N/A) |
|
Details | ||
| 6/17/2024 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/17/2024 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 6/7/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/6/2024 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2024 | Pliant Therapeutics | PLRX | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2024 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 6/3/2024 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2024 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/30/2024 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2024 | Exelixis | EXEL | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2024 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2024 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/7/2024 | Pliant Therapeutics | PLRX | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2024 | Schrodinger | SDGR | Maintain | Buy (N/A) |
|
Details | ||
| 4/16/2024 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2024 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2024 | Madrigal Pharmaceuticals | MDGL | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2024 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
246.56 (334.13) |
35.52% | Details | |
| 3/6/2024 | Crinetics | CRNX | New Coverage | Buy (N/A) |
43.51 (31.11) |
-28.5% | Details | |
| 2/29/2024 | Schrodinger | SDGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2024 | Cogent | COGT | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2024 | BridgeBio Pharma | BBIO | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2024 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 2/23/2024 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/8/2024 | Cogent | COGT | New Coverage | Buy (N/A) |
6.03 (12.49) |
107.13% | Details | |
| 2/7/2024 | Arrowhead Pharma | ARWR | Maintain | Neutral (N/A) |
|
Details | ||
| 1/8/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 12/19/2023 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2023 | Exelixis | EXEL | New Coverage | Buy (N/A) |
23.59 (44.47) |
88.51% | Details | |
| 11/7/2023 | BridgeBio Pharma | BBIO | New Coverage | Buy (N/A) |
28.83 (46.51) |
61.33% | Details | |
| 10/27/2023 | PTC Therapeutics | PTCT | Downgrade | Sell (Neutral) |
23.95 (47.63) |
98.87% | Details | |
| 10/18/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 10/9/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/19/2023 | Arrowhead Pharma | ARWR | New Coverage | Neutral (N/A) |
28.92 (16.76) |
-42.05% | Details | |
| 9/18/2023 | PTC Therapeutics | PTCT | Downgrade | Neutral (Buy) |
37.39 (47.63) |
27.39% | Details | |
| 8/4/2023 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2023 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2023 | Ionis Pharmaceuticals | IONS | Upgrade | Buy (Neutral) |
38.50 (41.76) |
8.47% | Details | |
| 7/25/2023 | Incyte | INCY | New Coverage | Buy (N/A) |
64.15 (67.86) |
5.78% | Details | |
| 5/24/2023 | Blueprint Medicines | BPMC | Maintain | Sell (N/A) |
|
Details | ||
| 5/24/2023 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 5/17/2023 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 5/4/2023 | Ionis Pharmaceuticals | IONS | Upgrade | Neutral (Sell) |
34.73 (41.76) |
20.24% | Details | |
| 4/27/2023 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/10/2023 | Pliant Therapeutics | PLRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2023 | Schrodinger | SDGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2023 | Ionis Pharmaceuticals | IONS | Maintain | Sell (N/A) |
|
Details | ||
| 2/21/2023 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Neutral (N/A) |
107.29 (57.29) |
-46.6% | Details | |
| 1/31/2023 | Schrodinger | SDGR | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2023 | Pliant Therapeutics | PLRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2023 | Intellia Therapeutics | NTLA | Upgrade | Neutral (Sell) |
33.85 (12.06) |
-64.37% | Details | |
| 11/29/2022 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 11/10/2022 | Ionis Pharmaceuticals | IONS | Maintain | Sell (N/A) |
|
Details | ||
| 11/9/2022 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2022 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/20/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/1/2022 | Mirum Pharamceuticals | MIRM | New Coverage | Buy (N/A) |
23.90 (51.93) |
117.28% | Details | |
| 9/1/2022 | Pliant Therapeutics | PLRX | New Coverage | Buy (N/A) |
18.11 (11.95) |
-34.01% | Details | |
| 9/1/2022 | Intellia Therapeutics | NTLA | New Coverage | Sell (N/A) |
60.24 (12.06) |
-79.98% | Details | |
| 9/1/2022 | PTC Therapeutics | PTCT | New Coverage | Buy (N/A) |
49.57 (47.63) |
-3.91% | Details | |
| 8/10/2022 | Ionis Pharmaceuticals | IONS | Maintain | Sell (N/A) |
|
Details | ||
| 6/21/2022 | Ionis Pharmaceuticals | IONS | Maintain | Sell (N/A) |
|
Details | ||
| 6/14/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2022 | Blueprint Medicines | BPMC | Downgrade | Sell (Neutral) |
64.50 (127.79) |
98.12% | Details | |
| 5/12/2022 | Ascendis Pharma | ASND | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2022 | Alnylam Pharmaceuticals | ALNY | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2022 | Blueprint Medicines | BPMC | Maintain | Neutral (N/A) |
|
Details | ||
| 3/1/2022 | Alnylam Pharmaceuticals | ALNY | New Coverage | Buy (N/A) |
155.00 (320.53) |
106.79% | Details | |
| 3/1/2022 | Schrodinger | SDGR | New Coverage | Buy (N/A) |
32.64 (21.45) |
-34.28% | Details | |
| 3/1/2022 | Blueprint Medicines | BPMC | New Coverage | Neutral (N/A) |
62.18 (129.46) |
108.2% | Details | |
| 3/1/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Sell (N/A) |
31.78 (34.73) |
9.28% | Details | |
| 3/1/2022 | Ascendis Pharma | ASND | New Coverage | Buy (N/A) |
108.52 (169.90) |
56.56% | Details |
